Walker-Warburg syndrome (WWS) is an autosomal recessive multisystem disorder characterized by complex eye and brain abnormalities with congenital muscular dystrophy (CMD) and aberrant a-dystroglycan glycosylation. Here we report mutations in the ISPD gene (encoding isoprenoid synthase domain containing) as the second most common cause of WWS. Bacterial IspD is a nucleotidyl transferase belonging to a large glycosyltransferase family, but the role of the orthologous protein in chordates is obscure to date, as this phylum does not have the corresponding non-mevalonate isoprenoid biosynthesis pathway. Knockdown of ispd in zebrafish recapitulates the human WWS phenotype with hydrocephalus, reduced eye size, muscle degeneration and hypoglycosylated a-dystroglycan. These results implicate ISPD in a-dystroglycan glycosylation in maintaining sarcolemma integrity in vertebrates.
Walker-Warburg syndrome (WWS) is an autosomal recessive multisystem disorder characterized by complex eye and brain abnormalities with congenital muscular dystrophy (CMD) and aberrant a-dystroglycan glycosylation. Here we report mutations in the ISPD gene (encoding isoprenoid synthase domain containing) as the second most common cause of WWS. Bacterial IspD is a nucleotidyl transferase belonging to a large glycosyltransferase family, but the role of the orthologous protein in chordates is obscure to date, as this phylum does not have the corresponding non-mevalonate isoprenoid biosynthesis pathway. Knockdown of ispd in zebrafish recapitulates the human WWS phenotype with hydrocephalus, reduced eye size, muscle degeneration and hypoglycosylated a-dystroglycan. These results implicate ISPD in a-dystroglycan glycosylation in maintaining sarcolemma integrity in vertebrates.
Defective O-linked glycosylation of α-dystroglycan is the characteristic feature of a clinically and genetically heterogeneous group of disorders commonly referred to as dystroglycanopathies. This group of diseases is characterized by a broad phenotypic spectrum ranging from severe forms of CMD with eye involvement, cerebral malformations and intellectual disability, including WWS and Muscle Eye Brain disease (MEB), to milder adult-onset phenotypes without central nervous system involvement, such as limb-girdle muscular dystrophy (LGMD) type 2I (ref. 1) . Mutations in six genes, POMT1, POMT2, POMGNT1, FKTN, FKRP and LARGE, encoding proteins involved in the posttranslational modification of α-dystroglycan, have been implicated in WWS and other dystroglycanopathies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Mutations in these six genes represent 35% of WWS incidence, suggesting that there are additional genes associated with WWS. At the milder end of the dystroglycanopathy disease spectrum, single individuals have been reported with α-dystroglycan hypoglycosylation due to missense mutations in either the DAG1 gene (encoding dystroglycan) 11 or the DPM3 gene 12 , with the latter leading to reduced levels of dolichol-P-mannose donor for O-mannosylation 12 . The factors determining dystroglycanopathy phenotypes are not well understood but may involve the extent of residual glycosylation of α-dystroglycan 1, 13, 14 and other proteins [15] [16] [17] . Identifying additional causative genes will shed light on the pathological mechanisms of WWS and other dystroglycanopathies.
To identify additional genes that are involved in WWS, we selected a cohort of 59 individuals with idiopathic WWS in whom mutations in the known dystroglycanopathy-linked genes had been previously excluded. Thirty of these individuals, the majority of whom Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan l e t t e r s came from consanguineous families, were genotyped using the Affymetrix GeneChip Human Mapping 250K SNP Nsp array to identify copy-number variants (CNVs) and homozygous regions. SNP haplotyping detected a large number of nonoverlapping homozygous regions among these individuals, providing support for further genetic heterogeneity in WWS ( Supplementary Fig. 1 ). Of note, the corresponding CNV profiles identified two homozygous deletions affecting the ISPD gene (in subjects WWS-160 and WWS-161; Supplementary Fig. 2) , suggesting that ISPD is a strong candidate for WWS, as there were no other overlapping CNV regions present in the cohort. Another family (WWS-25; for pedigree, see Supplementary Fig. 3a ) was identified with two siblings and a cousin affected with WWS who shared a 3.5-Mb homozygous region on chromosome 7p21 containing ten genes, including ISPD (Fig. 1a) . One of these siblings was investigated by exome sequencing and, after filtering based on an autosomal recessive pattern of inheritance according to methods described previously 18 , a single homozygous variant was identified in this region of shared homozygosity. This c.647C>A transversion in exon 3 of ISPD (NM_001101426.3), which is predicted to result in a p.Ala216Asp substitution, showed complete segregation in the family, being present in the homozygous state in the other two affected individuals, in the heterozygous state in both parental couples and absent in healthy or deceased siblings with another phenotype.
Next, we sequenced the ten coding exons of ISPD in the cohort of individuals with WWS and identified missense, nonsense and frameshift mutations in an additional five individuals from five families ( Supplementary Fig. 3 ). In addition, failure to PCR amplify exons 3 to 5 in family WWS-37 suggested the presence of a homozygous intragenic microdeletion, which was confirmed by quantitative multiplex ligation-dependent probe amplification (MLPA) analysis (data not shown). An overview of all identified mutations is given ( Table 1) , as is a schematic showing their locations ( Fig. 1a) . In summary, mutations affecting ISPD were detected in 9 out of 94 families, overall accounting for 10% of WWS cases ( Fig. 1b) . All mutations showed a segregation pattern expected for causative recessive mutations in family members available for testing and were absent in a control cohort of 3,712 haploid genomes. The three nonsense mutations, encoding p.Arg268*, p.Lys278* and p.Glu396*, are predicted to result in nonsense-mediated mRNA decay or truncation of the protein.
The three missense mutations (encoding p.Ala216Asp, p.Arg126His and p.Ala122Pro) are located within the ISPD domain ( Fig. 1a and Supplementary Fig. 4a ), a conserved domain of a large GT-A glycosyltransferase family that also includes nucleotidyltransferases 19 . Both the p.Ala216Asp and p.Arg126His alterations affect highly conserved Figure 1 Overview of genetic data in the cohort of individuals with WWS. (a) Schematic of the intragenic deletions, point mutations and homozygosity mapping data from families with WWS with ISPD mutations. The ideogram of chromosome 7 shows the 3.5-Mb region of common homozygosity at band 7p21.3 flanked by SNPs rs194034 and rs818323 that was identified in family WWS-25. The position of three partially overlapping intragenic deletions in ISPD is indicated above the intron-exon structure of the gene. At the bottom, the positions of homozygous and compound heterozygous mutations are shown with respect to the ISPD protein domain structure. (b) Identified mutations are shown by number and percentage per gene in our cohort of individuals with WWS and MEB. In total, 94 families were available for research, and prescreening revealed mutations in 1 of the 6 known WWS-linked genes in 35 families. l e t t e r s amino acids and are predicted to be damaging by PolyPhen2, whereas p.Ala122Pro is predicted to be probably damaging. In silico modeling based on a crystal structure of IspD in Escherichia coli using the HOPE web server (see URLs) predicted charge and size differences between the wild-type and mutant amino acids that are likely to affect protein folding and to disrupt the CTP-binding pocket in proteins with the p.Ala122Pro or p.Arg126His alteration ( Supplementary Fig. 4b ).
All affected individuals with ISPD mutations had a severe WWS-like phenotype, with only 2 out of 11 surviving beyond 2 years of age with brain anomalies that are more indicative of MEB (WWS-81 and WWS-163; Supplementary Table 1 ). Routine cerebral magnetic resonance imaging (MRI) ( Fig. 2a,b ) showed typical features of cobblestone lissencephaly together with hydrocephalus, cerebellar hypoplasia and a kinked brainstem. Muscle histology and immunohistochemistry showed dystrophic changes and a clear reduction of glycosylated α-dystroglycan, as detected with the IIH6 antibody that recognizes an unknown glyco-epitope on α-dystroglycan 20 (affected individuals from families WWS-25, WES-160 and WWS-81) ( Fig. 2c-f) .
The function of ISPD in vertebrates is unknown. In view of the high conservation between the protein orthologs of zebrafish (Danio rerio) and human (65% amino-acid similarity), we determined the effects of loss of function of zebrafish ispd, which encodes two isoforms that differ only in their N termini. To do this, we knocked down both ispd isoforms with antisense morpholino oligonucleotides (MOs) targeting exon-intron splice sites common to both transcripts ( Supplementary Fig. 5 ). High doses of ispd MO1 (7 ng) caused hydrocephalus and incomplete brain folding in 82% of embryos (n = 88) by 48 h post fertilization (h.p.f.) ( Fig. 3a and Supplementary  Fig. 6 ), as well as significantly reduced eye size reminiscent of microphthalmia in persons with WWS ( Fig. 3b,c) . Other phenotypic features included impaired motility and myotome lesions (data not shown). Injection with ispd MO2 (3 ng) caused similar morphological abnormalities, assuring the specificity of both MOs (Supplementary Fig. 7 ). We looked for structural defects in muscle fibers by labeling sarcolemma with membrane-localized red fluorescent protein (mRFP) and filamentous actin (F-actin) with phalloidin. ispd MO1-injected embryos showed muscle fiber degeneration by 72 h.p.f. (Fig. 3d) and, in some cases, disruption of myotendinous junctions (MTJs; 45%, n = 31), exemplified by elongated muscle fibers spanning MTJs (Fig. 3d) . Taken together, these results suggest that zebrafish ispd knockdown embryos recapitulate the major aspects of human WWS pathology.
Hypoglycosylation of α-dystroglycan is a diagnostic characteristic of WWS. To test whether knockdown of ispd in zebrafish also affected glycosylation of α-dystroglycan, we performed protein blotting with the IIH6 antibody 20 . Compared to control zebrafish embryos, glycosylated α-dystroglycan was reduced in ispd MO1-injected embryos ( Fig. 4a) . Given the similarity of MTJ disruption observed in ispd MO1-injected embryos and zebrafish laminin mutants 21, 22 , the localization of laminins was assessed. Despite severe muscle fiber degeneration, laminins remained localized to the MTJ in ispd MO1-injected embryos (Fig. 4b) . Subsequently, we assessed sarcolemma integrity in embryos injected with either ispd MO using Evans blue a b c d e f l e t t e r s dye (EBD). Intact sarcolemma is impermeable to EBD. We found that MTJ-anchored muscle fibers were infiltrated by EBD before the onset of muscle degeneration at 48 h.p.f. (Fig. 4c and Supplementary  Fig. 7c ). Muscle pathology became evident as EBD-infiltrated muscle fibers retracted during muscle degeneration. The posterior myotome of ispd MO1-injected embryos was more susceptible to sarcolemma damage than the anterior myotome ( Fig. 4c) . As sarcolemma damage was reported in dystrophin-deficient models 23, 24 , we assessed the immunoreactivity of dystrophin in ispd MO1-injected embryos. No obvious alterations to dystrophin immunoreactivity were detected (data not shown). Taken together, these results show an important pathogenic mechanism in WWS that is independent of laminin and dystrophin, with loss of Ispd function in zebrafish resulting in α-dystroglycan hypoglycosylation and compromised sarcolemma integrity preceding muscle fiber degeneration.
In plants, protozoa and some bacteria, ISPD belongs to the MEP pathway, which is absent in vertebrates 25 . Prokaryotic IspD has cytidyltransferase activity, using 2-C-methyl-D erythritol as a substrate for the synthesis of the nucleotide sugar CDP-methyl-erythritol. The structurally homologous TarI protein in Streptococcus pneumoniae, which lacks the MEP pathway, uses ribitol-1-phosphate to produce an activated nucleotide sugar (CDP-ribitol) that is incorporated into polysaccharides 26 . Analogous to the role of DPM3, it is likely that human ISPD synthesizes a new nucleotide sugar, the exact nature of which remains to be determined. Glycosyltransferases could use such nucleotide-activated building blocks for incorporation into α-dystroglycan O-mannosyl glycan. Of note, the bacterium Prevotella tannerae expresses a gene (ZP_05736246) with both IspD and lipopolysaccharide core D (LicD) domains, which may act sequentially in post-translational modifications. The LicD domain is also found in the putative glycosyltransferases FKTN and FKRP, both of which are involved in the glycosylation of α-dystroglycan. Thus, it seems that the ISPD and LicD domains that are both contained in a prokaryotic precursor protein have diverged into the vertebrate ISPD and FKTN-FKRP proteins, respectively. We sought to test the possibility of genetic interaction between these genes. Co-injection of subeffective doses of ispd MO1 with fktn or fkrp MO resulted in a marked increase in the proportion of embryos with hydrocephalus (68% and 49%, respectively, compared to 3% in embryos co-injected with control MO and ispd MO1; Fig. 4d and Supplementary Fig. 8a) . The same effect was seen using ispd MO2, confirming specificity (Supplementary Fig. 8) . Moreover, glycosylation of α-dystroglycan was reduced in embryos co-injected with ispd MO1 and fktn or fkrp MO compared to embryos co-injected with ispd MO1 and control MO and to embryos injected with fktn or fkrp MO alone (Fig. 4e) . These results support a cooperative interaction between ispd and fktn and fkrp in α-dystroglycan glycosylation. Figure 4 Hypoglycosylation of α-dystroglycan and disrupted sarcolemma integrity in ispd MO1-injected zebrafish embryos. (a) Protein blot analysis of microsome pellets and supernatant from embryos injected with control, ispd MO1 (7 ng) or dag1 (5 ng) MO at 48 h.p.f. Compared to control embryos, ispd MO1-injected embryos showed a reduction in glycosylated α-dystroglycan (IIH6; 76-102 kDa), with a slight decrease in β-dystroglycan, which is probably a secondary reduction due to protein instability caused by defective glycosylation of α-dystroglycan, as reported previously 27, 28 . Both glycosylated α-and β-dystroglycan were almost absent in dag1 MO-injected embryos. Equal protein loading was shown by Ponceau S staining (Pon S) and unknown glycoproteins detected by IIH6 antibody in all three lanes (<38 kDa). Equivalent amounts of γ-and acetylated tubulin were detected in the corresponding microsome supernatant. (b) Laminins remained localized to the MTJ in ispd MO1-injected embryos (7 ng). Positive fluorescent signal within degenerated muscle fibers (arrows) was probably due to disrupted sarcolemma integrity. Scale bar, 50 µm. 
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In conclusion, our findings provide evidence for ISPD mutations as a common cause of WWS. We report the identification of ISPD mutations in nine families with WWS. Because of the high frequency of ISPD mutations in this WWS cohort (15% of pre-screened affected individuals, 10% overall; Fig. 1b) , we recommend that ISPD mutation analysis should be performed as part of routine molecular diagnostic testing for WWS. With the identification of ISPD, we can now explain almost 50% of all occurrences of WWS in our cohort. The results of homozygosity mapping indicate the existence of several additional loci involved in WWS. Given that most of the remaining affected individuals in whom the genetic cause of WWS is unknown represent isolated cases, we anticipate that exome sequencing will be the strategy of choice to resolve additional genes and to unravel the complex post-translational modification pathways that are key to normal brain and muscular development. 
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Subject cohort, presequencing of known WWS-linked genes and CNV and homozygosity mapping studies. Informed consent was received after institutional ethical board approval for the research project was obtained from the Radboud University Nijmegen Medical Centre, Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem-Nijmegen Approval 2011/155. A cohort of 94 families with one or more children affected with WWS or MEB was available for study. In these families, mutations for one of the six screened WWS genes were identified in 35 affected individuals (37%). For 30 of the remaining 59 families, CNV analysis and homozygosity mapping was carried out using SNP arrays. Genomic DNA (250 ng) was digested by NspI before hybridization to the GeneChip Mapping 250K SNP Array Set (Affymetrix), following standard protocols to perform CNV analyses, as described 29 . Briefly, a Hidden Markov Model was used to predict the copy numbers and start and end positions of each CNV. To define losses and gains, a cutoff of four and seven consecutive SNP probes was used, respectively. For homozygosity mapping, genotype files were generated by Affymetrix GTC software and were analyzed using an in-house algorithm (J.v.R., unpublished data). Regions of excess homozygosity were identified using an algorithm adapted from one that has previously been described 30 , which calculated the number of contiguous homozygous SNPs required for significance in relation to degree of consanguinity for each individual. Haplotypes consistent with homozygosity in affected individuals were overlapped (Supplementary Fig. 1 ).
Next-generation sequencing and Sanger sequencing. The exome of one child affected with WWS from a consanguineous Turkish family (WWS-25) was sequenced using the SOLiD 4 system (Life Technologies), and the resulting DNA variants were integrated with familial homozygosity data in a variant prioritization scheme. Next-generation sequencing and analysis was carried out as described 18 , with the following alterations. Exome enrichment was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent), covering ~21,000 genes. The enriched exome library was pooled in equimolar concentrations in a set of four samples, including three other samples unrelated to WWS. The pool was based on a combined library concentration of 1 pM. Subsequently, the obtained pool was used for emulsion PCR and bead preparation using the EZbead system, following the manufacturer's instructions (Life Technologies). For each pool of four exome libraries, a full sequencing slide was used on a SOLiD 4 system, thereby anticipating that all four samples would be represented as a quarter of the total beads sequenced. A total of 5.56 Gb of mappable sequence was obtained. Raw sequencing statistics are available on request. Color space reads were mapped to the hg19 reference genome with SOLiD Bioscope software v1.3. Quality control settings included a requirement for the presence of at least five unique variant reads (different start sites), and the variant had to be present in at least 20% of all reads. Exclusion of known variants was based on dbSNPv132 and an in-house database including 177 in-house-analyzed exomes. The next filtering step was based on a recessive model of disease, keeping those variants that occurred in more than 80% of all reads, which is suggestive for homozygous changes.
Sequencing of exons of the ISPD gene was performed using traditional Sanger sequencing on ABI 310 or ABI 3100 Genetic Analyzers (Applied Biosystems). The sequences of oligonucleotides used for exon amplification are provided in Supplementary Table 2 .
Control cohort. A control cohort of 3,712 haploid genomes was interrogated for the presence of the identified mutations. This cohort included the results from 679 control individuals from the 1000 Genomes Project and approximately 2,000 control chromosomes from the University of Washington (Exome Variant Server), in addition to the 177 diploid exomes present in the in-house exome database.
Zebrafish studies
Antisense morpholino oligonucleotides. To simultaneously knock down both zebrafish ispd isoforms, two antisense MOs (Gene Tools) were designed against the exon-intron splice sites common to both ispd transcripts ( Supplementary   Fig. 5 ). For sequences of ispd MO1 and ispd MO2, see Supplementary Table 2 . Sequences of standard control, p53, dag1, fktn and fkrp MOs have been described [31] [32] [33] . MOs were injected into 1-or 2-cell-stage embryos at the specified concentrations.
Microsome preparation and protein blot analysis. Zebrafish embryos were de-yolked as described 32 , homogenized in pyrophosphate buffer containing Complete protease inhibitor cocktail (Roche) and centrifuged (14,000g) 34 . Protein was quantified using a Qubit Fluorometer (Invitrogen). Equal amounts of total protein were ultracentrifuged (142,000g) to obtain microsome pellets, which were then solubilized in TBS containing 1% Triton X-100 and protease inhibitors. The microsome supernatant and solubilized pellets were separated on 4-12% Bis-Tris gels (Invitrogen and transferred to PVDF membranes (Immobilon). Blots were probed with primary antibodies to glycosylated α-Dag1 (IIH6; Millipore, 05-593; 1:2,000 dilution), β-Dag1 (Novocastra, NCL-β-DG; 1:50 dilution), γ-tubulin (Sigma, T5326; 1:1,000 dilution) or acetylated tubulin (Sigma, T6793; 1:1,000 dilution). SuperSignal West chemiluminescent substrates (Pierce) were used to develop signals from horseradish peroxidase (HRP)-conjugated secondary antibodies.
RT-PCR and mRNA synthesis. Total RNA was extracted from control and MO-injected embryos using TRIzol (Invitrogen), and first-strand cDNA synthesis was performed using SuperScript III (Invitrogen) with either oligo(dT) or random hexamer primers. Primers for PCR are specified in Supplementary Table 2 . To label cell membranes in developing zebrafish embryos, a construct encoding membrane-localized red fluorescent protein (mRFP; gift from A.F. Schier (Harvard University)) was used to synthesize sense-strand capped mRNA 34 .
Zebrafish immunohistochemistry and Evans blue dye. Zebrafish embryos were fixed and incubated with primary antibodies, including rabbit antibody to laminins (Sigma, L9393; 1:400 dilution) and mouse antibodies to γ-tubulin (Sigma, T5326; 1:100 dilution) and dystrophin (Sigma, D8043; 1:100 dilution), using methods described previously 31 . Staining was visualized by Alexa Fluor 488-, 546-or 594-conjugated antibodies to rabbit or mouse immunoglobulin (Molecular Probes; 1:250 dilution), and embryos were then incubated in mounting medium with DAPI (Vector Labs) before analysis under confocal and differential interference contrast (DIC) microscopy. Zebrafish embryos were fixed and incubated with Alexa Fluor 488-conjugated phalloidin (Molecular Probes; 1:100 dilution) to label F-actin 15 . We injected 0.1% EBD (Sigma) into the pericardiac sinus of zebrafish embryos at 48 or 72 h.p.f., as previously described 15, 23, 35 , and analysis was carried out under confocal and DIC microscopy.
Statistical analysis.
Eye width measurements were plotted as mean ± s.d., and statistical significance was determined by the Student's t test assuming unequal variance. A P value smaller than 0.05 was considered to be statistically significant.
Protein modeling. ISPD protein modeling was carried out through the HOPE web server, which analyzes the structural and functional effects of point mutations by data mining information relating to the amino-acid sequence (UniProt), predictions (DAS), homology models (YASARA) and a calculation of the three-dimensional protein structure (WHAT IF) 36 , using the available E. coli model of IspD as a template 37 .
